Anti-vegf therapy

Anti-vegf therapy
Dermot McGrath
Dermot McGrath
Published: Friday, September 21, 2018
Bridging the gap between clinical trials and real-world outcomes Anti-VEGF agents have revolutionised the treatment of neovascular age-related macular degeneration, significantly reducing AMD-associated blindness and visual impairment in the process, according to Ursula Schmidt-Erfurth MD, PhD, at a special session on the EURETINA Guidelines for Management of Retinal Disease yesterday. Highlighting the achievements and challenges of current anti-VEGF therapy, Dr Schmidt-Erfurth said that intravitreal anti-VEGF therapy has significantly reduced the risk of vision loss in the major retinal diseases. “A miracle happens when we treat with a simple injection of anti-VEGF because a retina can become perfectly normal with this treatment. We know that anti VEGF therapy is beneficial for patients with a rapid, significant and maintained increase in vision and it is also beneficial for the economy given the massive investments involved,” she said. While there has been a significant improvement in therapeutic approaches to the treatment of exudative AMD in recent years, she noted that the impressive benefit of antiangiogenic therapy has not always carried over into real-world scenarios, with outcomes consistently less favourable than clinical trial results. Clinical trials have evaluated fixed one-, two- and three-monthly regimens and flexible PRN and treat-and-extend strategies, noted Dr Schmidt-Erfurth. “Many different approaches and strategies have been tried to bridge this gap between clinical trial data and real-world outcomes but the jury is still out on the optimal number to go before the monthly regimens. No decision has been made yet and there is a request for a global consensus on real world outcome measures to allow greater comparison of results. But this consensus has not been reached yet,” she said.
Latest Articles
ESCRS Today 2025: Happy Anniversaries!

ESCRS celebrates milestones with pioneers in IOLs, LASIK, femtosecond lasers, and corneal transplantation.

Read more...

ESCRS Today 2025: A Congress for Everyone

From YOs to families, the ESCRS Annual Meeting embraces full participation through inclusivity.

Read more...

ESCRS Today 2025: All Eyes on Innovation

Watching out for obstacles and opportunities

Read more...

Beyond the Numbers

Empowering patient participation fosters continuous innovation in cataract surgery.

Read more...

Thinking Beyond the Surgery Room

Practice management workshop focuses on financial operations and AI business applications.

Read more...

Aid Cuts Threaten Global Eye Care Progress

USAID closure leads retreat in development assistance.

Read more...

Supplement: ESCRS Clinical Trends Series: Presbyopia

Read more...

Debate: FS-LASIK or KLEx for Hyperopia?

FS-LASIK has more of a track record, but KLEx offers advantages.

Read more...

Four AI Applications Ready for Practice

Commercial offerings may save time, improve practice and research.

Read more...

Perioperative Medication Regimens for Cataract Surgery

Randomised controlled clinical trial results provide evidence-based guidance.

Read more...